AZN

AstraZeneca
NYSE

Real-time Quotes | Nasdaq Last Sale

50.17
+1.23
+2.51%
After Hours: 49.74 -0.43 -0.86% 16:34 02/21 EST
OPEN
49.88
PREV CLOSE
48.94
HIGH
50.25
LOW
49.68
VOLUME
4.11M
TURNOVER
--
52 WEEK HIGH
51.55
52 WEEK LOW
36.83
MARKET CAP
131.66B
P/E (TTM)
97.12
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AZN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AZN stock price target is 53.05 with a high estimate of 57.00 and a low estimate of 48.50.

EPS

AZN News

More
  • Top Stock Reports for Visa, JPMorgan & Bank of America
  • Zacks · 17h ago
  • Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
  • Zacks · 1d ago
  • Dems attack Trump over stalled efforts to lower drug prices
  • Seeking Alpha - Article · 1d ago
  • NASH: The Second Wave
  • Seeking Alpha - Article · 1d ago

Industry

Pharmaceuticals
+0.60%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About AZN

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
More

Webull offers kinds of AstraZeneca plc (ADR) stock information, including NYSE:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.